Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Elevance Health heads into Tuesday's Q3 results on the back of a 7% weekly gain, with the stock at $412.70 and the most notable pre-earnings signal coming not from the options market, but from its own CEO.
CEO Gail Boudreaux made two open-market purchases on July 17, the session after the stock fell nearly 13% on Q2 results, picking up a combined 2,725 shares for just over $1 million at prices around $366 to $368. A director, Ramiro Peru, bought a further 1,000 shares the same day at $366. These were discretionary purchases, none filed under a 10b5-1 plan, made at the low following the worst single-day reaction in recent memory. With the stock now trading roughly 12% above those buy prices, the cluster reads as conviction at a moment of maximum pessimism. The CFO's October 2 activity was a tax-withholding transaction tied to an award, a compensation mechanic rather than a directional bet.
The broader positioning around the print is deliberately quiet. Short interest at 2.3% of the free float has drifted lower by about 5% over the past month. Borrow costs have more than halved in a week to just 0.30%, and availability is effectively uncapped, all of which means the bear side of the trade carries no structural pressure. Options are equally subdued: the put/call ratio of 0.88 is marginally below its 20-day average and the z-score is essentially flat, so neither directional camp is loading up. The lending market and options market are both saying this stock is not heavily contested.
The analyst debate is anchored by the July collapse and what it revealed. Bulls, including Barclays, which raised its target to $469 this week maintaining Overweight, and TD Cowen at $465 with a Buy, point to a Medicare Advantage margin recovery story for 2026 and the company's scale as the largest Blue Cross Blue Shield provider serving 45 million members. Bears note that the July print itself delivered the evidence for their case: guidance implying a breakeven Medicaid margin, commercial headwinds, and an EPS estimate for 2026 that has been cut to around $25.54. The consensus target of $451 sits about 9% above the current price, but the range is wide, with Leerink's market perform target at $395 and Wells Fargo's overweight anchor at $473. Peer Humana jumped 11.6% Friday on what appears to be sector-specific news, while Centene and UnitedHealth posted more modest weekly gains, suggesting managed care sentiment is warming at varying degrees.
The Q3 print is therefore the first real test of whether the July guidance assumptions have held, whether Medicaid margins are tracking to the breakeven level management projected, and whether the Medicare Advantage margin improvement thesis is materialising on schedule.
See the live data behind this article on ORTEX.
Open ELV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
